



The
Patent
Office

GB 99/2828

9/70750

PC1/41522/U2020

INVESTOR IN PEOPLE

4

REC'D 11 OCT 1999
WIPO PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears a correction, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Signed *Andrew George*

Dated 17 September 1999

THIS PAGE BLANK (USPTO)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference GWS\20860

2. Patent application number
(The Patent Office will fill in this part)

9818756.0

27 AUG 1998

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Imperial College School of Medicine
St Mary's Hospital, Norfolk Place
London W2 1PG

Patents ADP number (if you know it)

07511009001

DCW 17/9/98

If the applicant is a corporate body, give the country/state of its incorporation

GB

Microbiological Research Authority

CAMR

Porton Down

Salisbury

Wiltshire SP4 0JG

UK

06765853601



4. Title of the invention

Superoxide dismutase as a vaccine antigen

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

MATHYS & SQUIRE
100 Grays Inn Road
London WC1X 8AL

Patents ADP number (if you know it)

1081001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

9. Enter the number of sheets for _____ of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description 13

Claim(s) 4

Abstract -

Drawing(s) -

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify) -

11.

I/We request the grant of a patent on the basis of this application.

Signature

Mathy & Squire

Date

27 August 1998

12. Name and daytime telephone number of person to contact in the United Kingdom

George W Schlich

0171 830 0000

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Superoxide Dismutase as a Vaccine Antigen

The present invention relates to pharmaceutical compositions for treating and/or vaccinating against bacterial infection and to methods of manufacturing such compositions. In particular, the invention relates to pharmaceutical compositions which comprise Cu,Zn-superoxide dismutase (Cu,Zn-SOD) or antibodies thereto.

At present most bacterial infections in humans or animals are treated after infection has set in by administration of antibiotic drugs. As many more strains of pathogenic bacteria become resistant to current antibiotics, the range of options open for treatment decreases. Moreover, many antibiotics can cause dangerous side effects upon individuals or animals taking them, for example allergy to penicillin or the toxicity of sulpha drugs. Furthermore, antibiotic treatment is sometimes only effective if the drug is taken regularly over a period of time thus maintaining a constant level of therapeutic agent in circulation. If individuals forget or are unable to maintain the course of antibiotic treatment then it may be rendered ineffective.

Some bacterial infections progress very quickly, sometimes too quickly for antibiotic treatment to have much effect unless administered at a very early stage in the course of the infection. Meningococcal disease is one example of such a virulent infection and is caused by the pathogen *Neisseria meningitidis*. In many cases symptoms of disease at first resemble those of influenza and thus infected individuals often delay in seeking medical attention. Vaccines based on polysaccharides present on the surface of some *N. meningitidis* serogroups are available at present but they show limited protection against infection. Moreover, the surface polysaccharide of serogroup B strains of *N. meningitidis* (causative agent of over half the cases of meningococcal disease in the UK) are only weakly immunogenic and are not included in current vaccines.

Accordingly, it is an object of the invention to provide a pharmaceutical composition comprising a vaccine antigen or an antibody that effectively protects against or ameliorates bacterial infection. It is a further object of the invention to

provide a pharmaceutical composition comprising a vaccine antigen that protects against meningococcal disease. It is yet a further object to provide a vaccine antigen that also provides protective immunity against a broader range of infectious bacteria. It is a further object to provide a method of manufacturing antibodies that can provide protective immunity to a range of bacterial pathogens when included in a pharmaceutical preparation. It is still a further object of the invention to provide a multivalent vaccine which provides protective immunity to a wide range of bacterial infections.

Cu,Zn-SOD is an metalloenzyme found in many prokaryotic and eukaryotic organisms. It catalyses the reduction of the superoxide radical anion, O_2^- , to hydrogen peroxide and molecular oxygen, thus playing an important role in the removal of cytotoxic free radicals from the organism. In bacteria Cu,Zn-SODs have been identified in the periplasm of a number of Gram negative species including *N. meningitidis*, *Haemophilus ducreyi*, *Haemophilus parainfluenzae*, *Actinobacillus pleuropneumoniae* and *Pasteurella multocida* (Kroll et al, 1995). The enzyme can exist as a dimer or a monomer, and examples of monomeric Cu,Zn-SODs are those from *Brucella abortus* and *Escherichia coli* (Pesce, et al, 1997). It is believed that Cu,Zn-SOD provides a defence for the bacterium against the burst of oxygen free radicals released by phagocytic host cells, such as macrophages, during infection (Wilks et al, 1998; Farrant et al, 1997).

A known attempt to utilise Cu,Zn-SOD as a vaccine antigen has not been successful. Tabatabai (Tabatabai and Pugh, 1994) showed that a synthetic fragment of a monomeric Cu,Zn-SOD (denoted as peptide 3) from *B. abortus* was able to provide a low level of immunity in mice against *Brucella* infection, but the level of protection provided was lower than that seen when using *Brucella* cell surface proteins and lipopolysaccharide antigens. Moreover, vaccination with the entire Cu,Zn-SOD failed to provide protective immunity at all. Tabatabai concluded that the antigenic fragment contained within *Brucella* Cu,Zn-SOD was counteracted by other parts of the protein which prevented it from eliciting an antigenic activity. This masking property was in fact so strong that even a mixture of synthetic

peptides that included peptide 3 elicited no protective immunity to *Brucella* infection. Thus the study by Tabatabai et al teaches against the use of either fragments of Cu,Zn-SOD or full length Cu,Zn-SOD as an effective antigen that could provide protective immunity to bacterial infection.

Cu,Zn-SODs from eukaryotes and most Gram negative bacteria form dimers in their native form. However, the Cu,Zn-SODs of *E.coli* and *B. abortus* are atypical in that they are normally monomeric (Pesce et al, 1997). In all Gram negative bacteria that produce Cu,Zn-SOD the protein is localised to the periplasmic space between the outer cell wall and the cell membrane.

The present invention relates to the surprising discovery that a monoclonal antibody raised against a recombinant Cu,Zn-SOD fusion protein from *A. pleuropneumoniae* has bactericidal activity against *N. meningitidis* and protects mice against challenge with *N. meningitidis*. Furthermore, a recombinant, dimeric Cu,Zn-SOD and immunogenic fragments from *A. pleuropneumoniae* (a pig pathogen) act as antigen that can confer protective immunity not only against this organism but also against other Gram negative human pathogens such as *N. meningitidis*, *H. ducreyi*, *H. parainfluenzae* and *P. multocida*. Thus the Cu,Zn-SOD is suitable as a vaccine component against both animal and human bacterial diseases such as meningococcal disease (caused by *N. meningitidis*) or chancroid (caused by *H. ducreyi*), or porcine pleuropneumonia (caused by *A. pleuropneumoniae*).

Accordingly, a first aspect of the present invention provides a composition comprising a Cu,Zn-SOD of the dimeric type, or a fragment, variant or derivative thereof, and a pharmaceutically acceptable carrier. The first aspect of the invention also provides a composition comprising a nucleic acid encoding a Cu,Zn-SOD of the dimeric type, or a fragment, variant or derivative thereof, and a pharmaceutically acceptable carrier. By "dimeric" we mean a SOD that naturally forms dimers under normal conditions. A pharmaceutically acceptable carrier could comprise an approved adjuvant such as alum or any other adjuvant approved for pharmaceutical purposes. The Cu,Zn-SOD can be from any bacteria, though especially from known

pathogenic bacteria, and from *N. meningitidis* as an example.

The present invention is not to be restricted to the use of full length or wild type Cu,Zn-SOD of the dimeric type. An antigenic fragment of the Cu,Zn-SOD may also be used in a vaccine formulation. The fragment preferably comprises a region of the Cu,Zn-SOD that is on the surface of the protein, although any fragment that confers protective immunity to bacterial infection is suitable; and the term "fragment" is intended to encompass any fragment against which an antibody may be raised which antibody binds intact, full length SOD. Moreover, mutant variants which have been modified to increase antigenicity or fusion protein derivatives between all or a part of a Cu,Zn-SOD and another protein for the purposes of purification or increasing antigenicity may also be suitable for use in pharmaceutical compositions. Vaccine components of the invention also include derivatives and variants of Cu,Zn-SOD. The term "derivative" is intended to encompass combinations of Cu,Zn-SOD with other proteins or molecules, including carbohydrates to form conjugate vaccines, the derivative retaining antigenicity such that an antibody raised against the derivative binds intact, full length SOD. The term "variant" is intended to encompass a polypeptide having an amino acid sequence that varies from that of intact, full length SOD, but such that antibodies raised against the variant bind intact, full length SOD.

In a preferred embodiment of the invention the pharmaceutical composition provides protection against meningococcal infection and/or disease. In further preferred embodiments of the invention the pharmaceutical composition provides protective immunity to infection from *Actinobacillus pleuropneumoniae*, *Pasteurellaceae* species, *Neisseria* species, *Haemophilus* species and other bacteria producing a Cu,Zn-SOD. In a specific embodiment of the invention the Cu,Zn-SOD is expressed from a recombinant gene cloned from *Actinobacillus pleuropneumoniae*.

It is an advantage of the present invention that a Cu,Zn-SOD of the dimeric type, or a fragment, variant or derivative thereof, can confer protective immunity to

infection from a broad range of bacterial pathogens. It is of further advantage that the present invention provides for pharmaceutical compositions comprising Cu,Zn-SODs, or a fragment, variant or derivative thereof, that are protective against bacterial infection in both humans and animals and in particular to meningococcal disease. It is of still further advantage that an antibody to a Cu,Zn-SOD from one species of bacteria can provide protective immunity to infection from a plurality of other species of bacteria, in particular that the invention provides protective immunity to meningococcal disease. A further advantage of the present invention is that Cu,Zn-SOD is relatively abundant and can be easily purified from bacterial cultures. Moreover, recombinant Cu,Zn-SODs can be fused to other proteins, such as glutathione-S-transferases, to facilitate purification from bacterial cultures expressing the fusion protein, and the Cu,Zn-SOD moiety retains both antigenicity and biological activity.

In use of the invention, a Cu,Zn-SOD is cloned from the pig pathogen *Actinobacillus pleuropneumoniae*, to give a recombinant form of the gene. The recombinant Cu,Zn-SOD gene is optionally linked to, such as by fusing, a glutathione-S-transferase gene to enable easy purification of the fusion protein when expressed in bacteria. A pharmaceutical preparation is prepared comprising the purified Cu,Zn-SOD protein and a pharmaceutically acceptable carrier; in one use the carrier includes the adjuvant alum. The pharmaceutical composition is suitably administered to the individual via any route. The nature or form of the composition may be selected from any conventional pharmaceutical composition including but not limited to tablets, capsules, oral compositions, liquids, compositions for infusion, syrups, solutions, powdered formulations and granular formulations. The pharmaceutical composition, in use, stimulates the individual to produce antibodies against the antigenic Cu,Zn-SOD protein, some of which provide protective immunity to a broad range of pathogens. In particular the pharmaceutical composition provides protective immunity to meningococcal disease.

A second aspect of the invention provides a vaccine comprising a Cu,Zn-SOD, or

a nucleic acid encoding a Cu,Zn-SOD, of the dimeric type, or a fragment, variant or derivative thereof.

In a specific embodiment of the invention the Cu,Zn-SOD of the dimeric type, or a fragment, variant or derivative thereof, is from a recombinant gene cloned from *Actinobacillus pleuropneumoniae*, though the invention also encompasses use of native proteins. In a further preferred embodiment the vaccine provides protective immunity against meningococcal meningitis.

Compositions and vaccines of the invention comprising a nucleic acid which encodes a Cu,Zn-SOD or fragment or derivative thereof are suitably prepared comprising the coding sequence inside a microparticle according to the methods of WO-A-97/17063, incorporated herein by reference.

A third aspect of the invention provides a method of preparing a pharmaceutical composition that consists of:-

- 1) cloning a gene for a Cu,Zn-SOD of the dimeric type to obtain a recombinant form of the gene; and
- 2)
 - (a) synthesising Cu,Zn-SOD from the recombinant gene; and combining said Cu,Zn-SOD with a pharmaceutically acceptable carrier, or
 - (b) combining said gene with a pharmaceutically acceptable carrier.

A fourth aspect of the invention provides for a pharmaceutical preparation comprising an antibody to a Cu,Zn-SOD of the dimeric type, or a fragment, derivative or variant thereof, and a pharmaceutically acceptable carrier. It is optional, but not essential, that the antibody is a monoclonal antibody.

The present invention thus also provides for an antibody preparation that is raised against a dimeric Cu,Zn-SOD, or a fragment, derivative or variant thereof, from one

species of Gram negative bacteria and that confers protective immunity to infection from this bacterium and also to infection from a plurality of other Gram negative bacteria. The antibody can be used in pharmaceutical preparations that confer passive immunity to bacterial infection upon a host organism. In the example described in more detail below a monoclonal antibody raised against Cu,Zn-SOD from *A. pleuropneumoniae* provides protection against *N. meningitidis* infection. Thus the monoclonal antibody is suitable for use in treating acute cases of meningococcal disease as well as in providing passive immunity to future meningococcal disease.

In a specific embodiment of the invention the antibody provides protective immunity to meningococcal disease. Thus it is suitable for use in preparations that provide passive immunity to infection and also for treatment of individuals already suffering from meningococcal infection.

In further specific embodiments of the invention the antibody provides protective immunity to bacterial infection from a range of bacterial pathogens including *Actinobacillus pleuropneumoniae*, *Pasteurellaceae* species, *Neisseria* species and *Haemophilus* species.

In a further preferred embodiment of the invention the antibody displays bactericidal activity. This activity may be directly attributed to the antibody itself or mediated via the complement system.

A fifth aspect of the invention provides for a multivalent vaccine comprising a plurality of Cu,Zn-SODs of the dimeric type, or fragments, derivatives or variants thereof, wherein said plurality of Cu,Zn-SODs are from the same or different species of Gram negative bacteria. A specific embodiment of the invention provides a multivalent vaccine comprising a plurality of Cu,Zn-SODs of the dimeric type, or fragments, derivatives or variants thereof, and one or a number of different bacterial proteins, or a fragment, derivative or variant thereof, that is not or are not a Cu,Zn-SOD. A further preferred embodiment of the invention is a multivalent

vaccine that provides protective immunity to meningococcal infection.

A sixth aspect of the invention provides for use of a Cu,Zn-superoxide dismutase of the dimeric type, or a fragment, derivative or variant thereof, in the manufacture of a vaccine against bacterial infection. In a preferred embodiment of the invention the use is in response to a bacterial infection due to Gram negative species of bacteria. In a specific embodiment of the invention the use is in response to a meningococcal infection.

A seventh aspect of the invention provides for an antibody specific to bacterial Cu,Zn-SOD of the dimeric type, or a fragment, derivative or variant thereof. A preferred embodiment of the invention provides for a monoclonal antibody (MAb) that is specific to bacterial Cu,Zn-SOD.

There now follows an example of a specific embodiment of the invention.

Example 1

Cu,Zn-SOD Monoclonal Antibody

Monoclonal antibodies (MAbs) were raised in mice against a glutathione-S-transferase fusion protein with the Cu,Zn-SOD from *Actinobacillus pleuropneumoniae*. The whole fusion protein as expressed in *E. coli* was found to be enzymically active. Of 72 potential hybridomas screened by western blotting, two recognised only *A. pleuropneumoniae* Cu,Zn-SOD, but one also recognised Cu,Zn-SOD from *H. parainfluenzae*, *H. ducreyi*, *N. meningitidis* and *A. actinomycetemcomitans*. The latter MAb was used for the passive protection studies.

Passive Protection

Three experiments were performed and all demonstrated that the MAb protects mice against lethal infections with *N. meningitidis*. Adult NIH mice were given an intra-peritoneal (ip) injection with antibody (50 μ l) per mouse 2h before challenge with *Neisseria meningitidis*. Mice were given further ip injections of antibody 2,5

and 24h after the challenge. The *N. meningitidis* challenge dose was the stated number of viable bacteria (see tables of results), given as an 0.5ml ip injection, containing 2mg iron dextran. At 24h mice were given a further 2mg iron dextran in an 0.2ml ip dose. Mice were then observed for 72h and the health of the animals noted. The results of these experiments are shown in the following tables.

VACCINE	CHALLENGE DOSE	SURVIVORS / CHALLENGED		
		DAY 1	DAY 2	DAY 3
growth medium	10^5	5/5	4/5	4/5
growth medium	10^6	5/5	3/5	3/5
50 μ l MAb	10^5	5/5	5/5	5/5
50 μ l MAb	10^6	5/5	5/5	5/5
5 μ l MAb	10^5	5/5	5/5	5/5
5 μ l MAb	10^6	5/5	4/5	4/5
Polyclonal serum *	10^5	5/5	5/5	5/5
Polyclonal serum *	10^6	5/5	5/5	5/5

* - raised against meningococcal outer membrane vesicles.

VACCINE	CHALLENGE DOSE	SURVIVORS/CHALLENGED		
		DAY 1	DAY 2	DAY 3
Growth medium	2×10^5	5/5	5/5	5/5
Growth medium	2×10^6	5/5	1/5	0/5
50 μ l MAb	2×10^5	5/5	5/5	5/5
50 μ l MAb	2×10^6	5/5	5/5	5/5
5 μ l MAb	2×10^5	5/5	5/5	5/5
5 μ l MAb	2×10^6	5/5	3/5	3/5
Polyclonal serum *	2×10^5	5/5	5/5	5/5
Polyclonal serum *	2×10^6	5/5	5/5	5/5

* - raised against meningococcal outer membrane vesicles.

EXPERIMENT 3					
VACCINE	CHALLENGE DOSE	SURVIVORS / CHALLENGED			
		DAY 1	DAY 2	DAY 3	DAY 4
Growth medium	1×10^7	5/5	0/5	0/5	0/5
50 μ l MAb	1×10^7	5/5	4/5	3/5	2/5
5 μ l MAb	1×10^7	5/5	1/5	0/5	0/5
Polyclonal serum	1×10^7	5/5	1/5	0/5	0/5
50 μ l Yersinia MAb	1×10^7	5/5	1/5	0/5	0/5
5 μ l Yersinia MAb	1×10^7	5/5	0/5	0/5	0/5

Bactericidal Activity

In addition to passive protective activity, the Cu,Zn-SOD MAb has been found to be bactericidal to two strains of meningococcus, with titres of 64-128 compared to a titre of 256 for a Group B polysaccharide specific MAb.

References:

Farrant, J.L. et al. (1997); Bacterial copper- and zinc- cofactored superoxide dismutase contributes to the pathogenesis of systemic salmonellosis; *Molecular Microbiology* **25**(4), 785-796.

Kroll, J.S., Langford, P.R, Wilks, K.E., Keil, A.D. (1995); Bacterial Cu,Zn-superoxide dismutase: phylogenetically distinct from the eukaryotic enzyme, and not so rare after all!; *Microbiology* **141**, 2271-2279.

Pesce, A. et al (1997); Unique structural features of the monomeric Cu,Zn-superoxide dismutase from *Escherichia coli* revealed by X-ray crystallography; *J. Mol. Biol* **274**, 408-420.

Tabatabai, L.B., Pugh, G.W. (1994); Modulation of immune responses in Balb/c mice vaccinated with *Brucella abortus* Cu,Zn-superoxide dismutase synthetic peptide vaccine; *Vaccine* **12**(10), 919-924.

Wilks, K.E. et al. (1998); Periplasmic superoxide dismutase in meningococcal pathogenicity; *Infection and Immunity*, **66**., 213-217.

CLAIMS:

1. A pharmaceutical composition comprising (i) a Cu,Zn-superoxide dismutase (Cu,Zn-SOD) of the dimeric type, or a fragment, variant or derivative thereof, or (ii) a nucleic acid coding therefor, and a pharmaceutically acceptable carrier.
2. A pharmaceutical composition according to Claims 1, wherein said composition provides protection against meningococcal infection.
3. A pharmaceutical composition according to Claim 1 or 2, wherein said composition provides protective immunity to *Actinobacillus pleuropneumoniae* infection.
4. A pharmaceutical composition according to Claims 1 or 2, wherein said composition provides protective immunity to *Pasteurellaceae* infection.
5. A pharmaceutical composition according to Claim 1 or 2, wherein said composition provides protective immunity to *Neisseria* infection.
6. A pharmaceutical composition according to Claims 1 or 2, wherein said composition provides protective immunity to *Haemophilus* infection.
7. A pharmaceutical composition according to any previous claim, wherein the Cu,Zn-SOD is obtainable from a recombinant gene cloned from bacteria.
8. A vaccine comprising (i) a Cu,Zn-superoxide dismutase (Cu,Zn-SOD) of the dimeric type, or a fragment, variant or derivative thereof, or (ii) a nucleic acid coding therefor.
9. A vaccine according to Claim 7, wherein the Cu,Zn-SOD is obtainable from a recombinant gene cloned from bacteria.

10. A vaccine according to Claims 7 or 8, wherein said vaccine provides protection against meningococcal infection.
11. A method of preparing a pharmaceutical composition comprising:-
 - 1) cloning a gene for a Cu,Zn-SOD of the dimeric type to obtain a recombinant form of the gene; and
 - 2) (a) synthesising Cu,Zn-SOD from the recombinant gene; and combining said Cu,Zn-SOD with a pharmaceutically acceptable carrier, or
(b) combining said gene with a pharmaceutically acceptable carrier.
12. A pharmaceutical preparation comprising an antibody to a Cu,Zn-SOD of the dimeric type, or a fragment, derivative or variant thereof, and a pharmaceutically acceptable carrier.
13. A pharmaceutical preparation according to Claim 12, wherein said antibody provides protective immunity to meningococcal disease.
14. A pharmaceutical composition according to Claims 12 and 13, wherein said composition provides protective immunity to *Actinobacillus pleuropneumoniae* infection.
15. A pharmaceutical composition according to Claim 12 or 13, wherein said composition provides protective immunity to *Pasteurellaceae* infection.
16. A pharmaceutical composition according to Claim 12 or 13, wherein said composition provides protective immunity to *Neisseria* infection.
17. A pharmaceutical composition according to Claims 12 or 13, wherein said

composition provides protective immunity to *Haemophilus* infection.

18. A pharmaceutical composition according to any of Claims 12 to 17, wherein said antibody displays bactericidal activity.
19. A multivalent vaccine comprising a plurality of Cu,Zn-SODs of the dimeric type, or fragments, derivatives or variants thereof, wherein said plurality of Cu,Zn-SODS are from the same or different species of Gram negative bacteria.
20. A multivalent vaccine comprising a Cu,Zn-SOD of the dimeric type, or fragments, derivatives or variants thereof, and a second protein, or a fragment, derivative or variant thereof, that is not a Cu,Zn-SOD.
21. A multivalent vaccine according to Claims 16 or 17, wherein said vaccine provides protective immunity to meningococcal disease.
22. Use of a Cu,Zn-superoxide dismutase of the dimeric type, or a fragment, derivative or variant thereof, in the manufacture of a vaccine against bacterial infection.
23. Use according to Claim 22, wherein the bacterial infection is due to Gram negative species of bacteria.
24. Use according to Claim 22 or 23 wherein the bacterial infection is due to meningococcal infection.
25. An antibody specific to bacterial Cu,Zn-SOD of the dimeric type, or a fragment, derivative or variant thereof.
26. A monoclonal antibody according to Claim 25.

27. Use of a nucleic acid encoding a Cu,Zn-superoxide dismutase of the dimeric type, or a fragment, derivative or variant thereof, in the manufacture of a vaccine against bacterial infection.

PCT/US99/02828

27/8/99 cr

Mathys + Squier

THIS PAGE BLANK (USPTO)